
Novartis Ensures Continued Malaria Drug Production Despite Aid Challenges
GHealth News - In a powerful commitment to global health, Novartis has announced it will continue producing life-saving malaria and leprosy medicines, even if orders stop due to global aid funding cuts. Speaking to Reuters, Dr. Lutz Hegemann, President of Global Health at Novartis, stressed that the company will not be the bottleneck in access to essential treatments.
Despite the unstable future of key funding sources like the U.S. President’s Malaria Initiative and broader donor pullbacks, Novartis will maintain its annual output of 28 million malaria treatments at not-for-profit pricing. It will also continue donating leprosy drugs through the WHO.
Beyond supply, Novartis is ramping up its R&D investment in neglected tropical diseases, doubling its pledge to $490 million by 202...